- Home
- MODD vs APLT Comparison
MODD vs APLT Comparison
Compare MODD & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | APLT |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MODD | APLT |
|---|---|---|
| Price | $0.34 | $0.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 487.1K | ★ 27.2M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.11 |
| 52 Week High | $1.68 | $1.50 |
Technical Indicators
Market Signals| Indicator | MODD | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 25.40 |
| Support Level | $0.30 | $0.21 |
| Resistance Level | $0.47 | $0.26 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 35.06 | 5.13 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.